1. Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, randomized trial. Issue 2 (3rd January 2021) Authors: Ji, Linong; Dong, Xiaolin; Li, Yiming; Li, Yufeng; Lim, Soo; Liu, Ming; Ning, Zu; Rasmussen, Søren; Skjøth, Trine Vang; Yuan, Guoyue; Eliaschewitz, Freddy G. Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 2(2021) Page Start: 404 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗